- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04345653
Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers
Study Overview
Detailed Description
Given the lack of data regarding use of HCQ for COVID-19 prevention in healthy participants in midst of pandemic crisis, this study proposes an expedited feasibility study focusing on safety and early efficacy.
Prior to HCQ administration, baseline SARS-CoV-2 and other baseline biomarker testing will be conducted. During the 4-week study period, participants will be monitored for drug related adverse events and assessed for development of COVID. SARS-CoV-2 assay and biomarker testing will be repeated at the end of four-week study. Safety outcomes will be assessed by the number of adverse events (AEs) and their severity; and early efficacy as the number of participants who tested positive at the end of the 4-week period comparing to data collected by occupational Health regarding the total number of high-risk healthcare workers that were tested positive during the same period and historical controls from known high risk infection rates. An exploratory analysis of inflammatory regulation and immunomodulatory markers by HCQ and its effect on possible disease modification based on previously studied pathophysiological mechanism of COVID-19.
The broader aim of this study is to set a precedent to facilitate a large-scale emergent public health intervention. Purpose would be to mitigate, or abort further transmission of COVID-19. Given that COVID-19 transmission has occurred prior to initiation of this study, the rationale for this intervention is based on prior epidemiological evidence. Post-infectious or vaccination-induced immunity in at least 30% of population at-risk has been shown to mitigate or abort propagation of a local epidemics and global pandemic. This would help flatten the curve of the disease progression, until such time that a vaccine may become available. Data from this study will be used to design and implement a population-based phase IIb/III randomized clinical trial.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
Edison, New Jersey, United States, 08820
- Hackensack Meridian Health - JFK Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Volunteers ages 18 to 99 years,
- Able to sign own informed consent form,
- Considered high-risk healthcare care providers in a hospital setting with active exposure to COVID-19 infection.
High-risk healthcare providers are defined as those actively working during the study duration in the Emergency Department and in the Intensive Care Setting, for the purpose of this study.
Exclusion Criteria:
- Inability to tolerate an oral medication or known allergy to chloroquine or hydroxychloroquine
- Pregnancy or breast-feeding
- Immunocompromised status, hepatic failure, electrolytic imbalance
- Creatinine clearance (CCL) <30 mL/min
- Prolonged QT interval (QTc > 450ms for males and QTc > 470 for females)
- Confirmed COVID-19 infection on baseline testing
- Has another known contraindication to treatment with the study drug, including retinopathy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Study arm - Hydroxychloroquine Sulfate (HCQ)
HCQ sulfate HCQ 400mg (2x 200mg tablets) by mouth 6-12 hours apart on day 1, followed by 3 weeks of weekly 400mg (2x 200mg tablets) by mouth
|
Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment Feasibility
Time Frame: Study period, up to two months from the day the first participant was screened
|
To evaluate the feasibility of this protocol including participants' recruitment within the estimated time frame, i.e. understand the ability of the team to identify eligible participants, enroll them, retain them and follow them up until study completion.
|
Study period, up to two months from the day the first participant was screened
|
Resource Utilization
Time Frame: Study period, up to two months from the day the first participant was screened
|
To evaluate the utilization of tests and drug for this study in consideration with the limited availability of both for research purposes as reflected on the number of participants that got tested and received at least one dose of the drug.
|
Study period, up to two months from the day the first participant was screened
|
Safety as Reflected on the Number and Severity of Adverse Events and Serious Adverse Events
Time Frame: 28 day post enrollment
|
To Determine the Safety profile for a previously well studied drug in this select group of HCP.
Incidence of well described side effects would be studied over the course of the study and will be compared with the side effects and their prevalence as described in the Pharmacy manual for HCQ.
|
28 day post enrollment
|
Early Feasibility as Reflected on the Number of Participants Contracting COVID-19 (10% or Less) in Comparison to the Expected 30% as Per CDC.
Time Frame: 28 day post enrollment
|
To evaluate the early efficacy of HCQ in high-risk, healthy volunteers in the prevention of acquiring COVID-19 while continuing to follow standard precautions that meet or exceed Centers of Disease Control (CDC) guidelines.
|
28 day post enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jawad Kirmani, MD, Hackensack Meridian Health Corporation
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Hydroxychloroquine
Other Study ID Numbers
- Pro2020-0356
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Hydroxychloroquine Sulfate (HCQ)
-
Kimberly Perez, MDEli Lilly and CompanyCompleted
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityUnknown
-
RedHill Biopharma LimitedCompletedCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, IntrahepaticUnited States
-
Hospital Israelita Albert EinsteinHospital do Coracao; Hospital Sirio-Libanes; Brazilian Research In Intensive... and other collaboratorsCompletedCoronavirus Infections | Pneumonia, ViralBrazil
-
University of WashingtonBill and Melinda Gates FoundationCompletedCOVID-19 | Corona Virus Infection | SARS-CoV-2 | SARS (Severe Acute Respiratory Syndrome)United States
-
Abramson Cancer Center at Penn MedicineJohns Hopkins University; Pfizer; Translational Breast Cancer Research Consortium and other collaboratorsRecruitingBreast CancerUnited States
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedHealthy Participants | Rheumatoid Arthritis (RA) PreventionUnited States
-
Makerere UniversityActive, not recruiting
-
Shanghai Children's HospitalRecruitingAlport Syndrome, X-LinkedChina